pTVG-AR

BIOLOGICAL3 trials

Sponsors

University of Wisconsin, Madison

Conditions

Castration-resistant Prostate CancerMetastatic CancerProstate Cancer

Phase 1

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

CompletedNCT02411786

University of Wisconsin, MadisonProstate Cancer

Start: 2015-08-24End: 2020-11-28Updated: 2021-02-04

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

RecruitingNCT04989946

University of Wisconsin, MadisonProstate Cancer

Start: 2021-12-16End: 2028-12-01Target: 60Updated: 2026-01-28

Phase 2

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Active, not recruitingNCT04090528

University of Wisconsin, MadisonCastration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer

Start: 2019-10-21End: 2026-10-31Updated: 2025-12-05

Related Papers

Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.

2026-03-04

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer2022-03-0147 citations